<DOC>
	<DOCNO>NCT01650909</DOCNO>
	<brief_summary>This study independent sub-study protocol title PKU-016 : A double-blind , placebo-controlled , randomize study evaluate safety therapeutic effect sapropterin dihydrochloride neuro-psychiatric symptom subject phenylketonuria ( PKU ASCEND ) . The primary objective study determine oxidative stress patient classical phenylketonuria ( PKU ) enrol PKU-016 , use brain scan ( call HMPAO SPECT ) baseline 26 week , blood redox biomarkers .</brief_summary>
	<brief_title>The Effects Sapropterin Dihydrochloride Supplementation Vivo Redox Status Patients With Classical PKU</brief_title>
	<detailed_description />
	<mesh_term>Phenylketonurias</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Substudy Inclusion criterion main study : ≥ 8 year age Confirmed diagnosis PKU Willing continue current diet ( typical diet 3 month prior study entry ) unchanged participate study Willing able provide write , sign inform consent case subject age 18 , provide write assent ( require ) write informed consent legally authorize representative nature study explain , prior researchrelated procedure Sexually active subject must willing use acceptable method contraception participate study least 30 day follow last dose sapropterin dihydrochloride Females childbearing potential must negative pregnancy test screen willing additional pregnancy test study . Females consider childbearing potential include menopause least 2 year , tubal ligation least 1 year prior screening , total hysterectomy Willing able comply study procedures All substudy Exclusion criterion main study : Has know hypersensitivity sapropterin dihydrochloride excipients Subject breastfeed screen plan become pregnant ( subject partner ) time study Use investigational product investigational medical device within 30 day prior screen , requirement investigational agent prior completion schedule study assessment Received sapropterin dihydrochloride within 16 week randomization • Have initiate adjusted medication treatment ADHD , depression , anxiety ≤ 8 week prior randomization Taking medication know inhibit folate synthesis ( eg , methotrexate ) Any condition require treatment levodopa PDE5 inhibitor Concurrent disease condition would interfere study participation , compliance safety determine Investigator Any condition , view Investigator , place subject high risk poor treatment compliance completing study</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>